mRNA cancer vaccine
An emerging class of immunotherapeutics designed to stimulate the immune system to recognize and attack cancer cells by delivering mRNA encoding tumor-associated antigens.
Key Developments
- Moderna & Merck Collaboration: Positive Phase 3 trial results announced for a personalized mRNA cancer vaccine targeting resected melanoma.
- The vaccine candidate is known as Intismeran (also referred to as Autogene).
- It is administered as adjuvant therapy in combination with Keytruda (pembrolizumab).
- Moderna Merck mRNA Cancer Vaccine and Keytruda for Resected Melanoma Adjuvant Therapy
- Significance: Represents a major advancement in personalized cancer treatment, leveraging the speed of mRNA technology for patient-specific neoantigen targeting.
Related Concepts
- Immunotherapy
- Neoantigen
- Pembrolizumab
- Personalized Medicine
References
- Moderna Merck mRNA Cancer Vaccine and Keytruda for Resected Melanoma Adjuvant Therapy (Hank Green, 2026-08-29)